For Q1 FY2026 (ended March 31, 2026), Nuvation Bio reported revenue of $83.2 million, a significant increase of 2,598.7% year-over-year. Net income was $5.4 million, compared to a net loss in the prior year, with diluted EPS of $0.01. Operating income was $3.9 million, and the company held $125.4 million in cash with total equity of $319.6 million.
•Revenue surged to $83.2M, up 2,598.7% YoY.
•Net income of $5.4M vs. prior year loss; EPS $0.01.
•Operating income of $3.9M, a turnaround from prior year.
•Cash and equivalents of $125.4M; equity of $319.6M.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer.
It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. Founded in 2018, the company is headquartered in New York, New York.
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer treatment. Its lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor designed to treat patients with ROS1-positive non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1, currently in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma. Founded in 2018 and headquartered in New York, New York, Nuvation Bio operates in the biotechnology industry within the healthcare sector, aiming to address unmet medical needs in oncology.
On which stock exchange is Nuvation Bio listed and what currency is used?
Nuvation Bio Inc. is listed on the New York Stock Exchange (NYSE) under the ticker symbol NUVB. The company trades in US dollars (USD), as it is based in the United States. Being listed on a major US exchange provides liquidity and visibility to investors, and the use of USD facilitates trading for both domestic and international investors.
What sector and industry does Nuvation Bio belong to?
Nuvation Bio Inc. operates in the healthcare sector, specifically within the biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing drug candidates for cancer treatment. Biotechnology companies like Nuvation Bio typically engage in high-risk, high-reward research, aiming to bring innovative therapies to market. The company's primary area of focus is oncology, with its lead programs targeting specific genetic mutations in cancers such as non-small cell lung cancer and astrocytoma.
Where is Nuvation Bio headquartered and what markets does it serve?
Nuvation Bio Inc. is headquartered in New York, New York, United States. As a clinical-stage company, its primary market is the United States, where it conducts clinical trials and seeks regulatory approvals. The company's therapies are designed to address global cancer treatment needs, but its current operations and clinical development are centered in the US. The company was founded in 2018 and has since been advancing its pipeline of oncology candidates.
What are the main product candidates of Nuvation Bio?
Nuvation Bio Inc.'s main product candidates include IBTROZI (taletrectinib) and Safusidenib. IBTROZI is a ROS1 inhibitor being developed for the treatment of patients with ROS1-positive non-small cell lung cancer, a type of lung cancer driven by ROS1 gene fusions. Safusidenib is an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1), currently in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma, a type of brain tumor. Both candidates target specific genetic alterations in cancers, reflecting the company's precision medicine approach.